AG
ARQT icon

Algert Global’s Arcutis Biotherapeutics ARQT Stock Holding History

Algert Global’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Sell
19,090
-17,630
-48% -$411K 0.01% 1070
2026
Q1 		$865K Sell
36,720
-49,540
-57% -$1.26M 0.01% 887
2025
Q4 		$2.5M Sell
86,260
-143,132
-62% -$3.66M 0.04% 652
2025
Q3 		$4.32M Buy
229,392
+130,637
+132% +$2.06M 0.07% 451
2025
Q2 		$1.38M Sell
98,755
-22,125
-18% -$310K 0.03% 735
2025
Q1 		$1.89M Buy
120,880
+40,090
+50% +$565K 0.05% 617
2024
Q4 		$1.13M Buy
80,790
+8,310
+11% +$91K 0.03% 751
2024
Q3 		$674K Buy
72,480
+62,065
+596% +$612K 0.02% 838
2024
Q2 		$96.9K Buy
+10,415
New +$94.2K ﹤0.01% 1394
2022
Q4 		– Sell
-22,126
Closed -$423K – 1128
2022
Q3 		$423K Buy
+22,126
New +$501K 0.03% 856

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Algert Global's ARQT Position: Q2 2026 in Review

Algert Global reduced its Arcutis Biotherapeutics (ARQT) stake by 48% in Q2 2026, selling an estimated $411K and leaving 19,090 shares worth $501K. The position accounts for 0.01% of the portfolio, ranked #1070.

Algert Global first reported a position in ARQT in Q3 2022 and has held it in 10 quarters since. The position peaked at $4.32M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Algert Global held 19,090 shares of Arcutis Biotherapeutics worth $501K as of Q2 2026.
  • Algert Global sold 17,630 Arcutis Biotherapeutics shares in Q2 2026, an estimated $411K.
  • Arcutis Biotherapeutics made up 0.01% of Algert Global's portfolio in Q2 2026, its #1070 holding.
  • Algert Global first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 10 quarters since.
  • Algert Global's Arcutis Biotherapeutics position peaked at $4.32M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.